Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Urokinase Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Non-invasive Evaluation of Aggressiveness: a Prospective Phase II Clinical Trial Comparing with Gleason Score

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Limited diagnostic utility of Chromogranin A measurements in workup of neuroendocrine tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Blocking of efflux transporters in rats improves translational validation of brain radioligands

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The aim of this study was to evaluate the correlation between uptake of the positron emission tomography (PET) ligand 68Ga-NOTA-AE105 targeting the urokinase-type plasminogen activator receptor (uPAR) and Gleason score in patients undergoing prostate biopsy. Materials & Methods: Patients with clinical suspicion of prostate cancer (PCa) or previously diagnosed with PCa were prospectively enrolled in this phase II trial. A combined uPAR PET, multiparametric magnetic resonance imaging (mpMRI) was performed and standardized uptake value (SUV) from primary tumor, as delineated by mpMRI, was measured by two independent readers. Correlation between SUV and Gleason score obtained by biopsy was assessed. Results: A total of 27 patients had histologically verified PCa visible on mpMRI and constituted the study population. There was a positive correlation between SUVmax and Gleason score (Spearman's rho= 0.55; P = 0.003). Receiver operating characteristics analysis showed an area under the curve (AUC) of 0.88 (95%CI: 0.67-1.00) in discriminating Gleason score ≥3+4 from ≤3+3. A cut-off for tumor SUVmax could be established with a sensitivity of 96% (79-99%) and specificity of 75% (30-95%) in detecting Gleason Scores ≥3+4. For discriminating Gleason score ≥ 4+3 vs. ≤ 3+4, a cut-off could be established for detecting Gleason score ≥ 4+3 with a sensitivity of 93% (69-99%) and specificity of 62% (36-82%). Conclusion: SUV measurements from uPAR PET in primary tumors as delineated by mpMRI showed a significant correlation with Gleason score, and tumor SUVmax was able to discriminate between low-risk and intermediate risk Gleason score profiles with high diagnostic accuracy. Consequently, uPAR PET/MRI could be a promising method for non-invasive evaluation of PCa, which may in the future potentially reduce the need for repeated biopsies, e.g. in active surveillance.

OriginalsprogEngelsk
TidsskriftJournal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN0161-5505
DOI
StatusE-pub ahead of print - 6 aug. 2020

Bibliografisk note

Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

ID: 60880060